AbbVie shells out $5.8bn in cash and stock for cancer firm Stemcentrx
Continuing to build its oncology pipeline, AbbVie Inc. is paying $5.8bn--$2bn in cash and $3.8bn in stock--to acquire private cancer-focused firm Stemcentrx Inc. AbbVie could also shell out up to $4bn in cash related to clinical development and regulatory earn-outs.
- Gene Therapy, Cell Therapy
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.